Papillary Adenocarcinoma of the Kidney, with Aortography Resembling Huge Renal Cyst

Salvin, Benjamin L.; Schloss, Walter A.

doi:10.1016/s0022-5347(17)67557-8

Cited by 4 publications

(1 citation statement)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The precise histogenesis has not yet been determined; however, it is believed to originate from the proximal tubule epithelial cells, as is the case with ccRCC [30]. Although sporadic descriptions of papillary renal cancer date back to the 1950s [31] and 1960s [32], pRCC was firstly and comprehensively described by Mancilla-Jimenes in 1976 [33,34]. The traditional distinction in type 1 and type 2 pRCC was formally described by Delahunt and Eble in 1997 [35].…”

Section: Classification Of Prccmentioning

confidence: 99%

Long Non-Coding RNAs as Novel Biomarkers in the Clinical Management of Papillary Renal Cell Carcinoma Patients: A Promise or a Pledge?

Trevisani

Floris

Vago

et al. 2022

Cells

View full text Add to dashboard Cite

Papillary renal cell carcinoma (pRCC) represents the second most common subtype of renal cell carcinoma, following clear cell carcinoma and accounting for 10–15% of cases. For around 20 years, pRCCs have been classified according to their mere histopathologic appearance, unsupported by genetic and molecular evidence, with an unmet need for clinically relevant classification. Moreover, patients with non-clear cell renal cell carcinomas have been seldom included in large clinical trials; therefore, the therapeutic landscape is less defined than in the clear cell subtype. However, in the last decades, the evolving comprehension of pRCC molecular features has led to a growing use of target therapy and to better oncological outcomes. Nonetheless, a reliable molecular biomarker able to detect the aggressiveness of pRCC is not yet available in clinical practice. As a result, the pRCC correct prognosis remains cumbersome, and new biomarkers able to stratify patients upon risk of recurrence are strongly needed. Non-coding RNAs (ncRNAs) are functional elements which play critical roles in gene expression, at the epigenetic, transcriptional, and post-transcriptional levels. In the last decade, ncRNAs have gained importance as possible biomarkers for several types of diseases, especially in the cancer universe. In this review, we analyzed the role of long non-coding RNAs (lncRNAs) in the prognosis of pRCC, with a particular focus on their networking. In fact, in the competing endogenous RNA hypothesis, lncRNAs can bind miRNAs, resulting in the modulation of the mRNA levels targeted by the sponged miRNA, leading to additional regulation of the target gene expression and increasing complexity in the biological processes.

show abstract

Section: Classification Of Prccmentioning

confidence: 99%